CICC Maintains Outperform on ZYLOXTB with HK$32 Target, Highlights Strategic Investment in LIFETECH SCI to Expand Platform

Stock News11-09

CICC has maintained its "Outperform" rating on ZYLOXTB (ASX: 02190) with a target price of HK$32, based on a discounted cash flow valuation model with a weighted average cost of capital of 11.4% and a perpetual growth rate of 2.2%. The target price implies price-to-earnings ratios of 26x for 2026 and 20x for 2027, representing approximately 65% upside from the current share price. The investment bank also kept its adjusted net profit forecasts for the company unchanged at RMB 385 million for 2026 and RMB 484 million for 2027.

On November 6, ZYLOXTB announced a proposed strategic investment in LIFETECH SCI alongside Deyfo Capital, along with a placement of new H shares to an entity under Deyfo. CICC believes this strategic investment is expected to expand the company's platform layout, with the complementary nature of both parties' product portfolios and market channels being worth anticipating.

Strategic Investment Expands Platform Layout

ZYLOXTB plans to contribute approximately HK$889 million for a 60% equity stake in the investment platform. The platform will subscribe to new shares of LIFETECH SCI for approximately HK$1.482 billion, resulting in an approximately 16.7% shareholding upon completion, with ZYLOXTB indirectly entitled to approximately 10% economic interest. Meanwhile, Deyfo Capital plans to subscribe to 39.8 million new shares of ZYLOXTB at HK$22 per share, a 13.5% premium to the closing price on the announcement date, with expected net proceeds of approximately HK$864 million. On the operational side, ZYLOXTB management will assume the roles of CEO and CFO at LIFETECH SCI. At this stage, both parties will maintain their status as independent listed companies, with LIFETECH SCI's major decisions subject to its board of directors.

Operational and R&D Synergies Worth Anticipating

The announcement noted that the product portfolios and market channels of both parties are complementary. CICC assesses that ZYLOXTB's neurovascular and peripheral intervention layout combined with LIFETECH SCI's aortic and structural heart products can enhance commercialization efficiency through sharing of physician and distributor resources and cross-border overseas sales. Complementary R&D and manufacturing experience can also help optimize product development processes and operational efficiency.

Focus on Earnings Contribution and Shareholder Returns

This investment is accompanied by an expansion of ZYLOXTB's share capital. CICC judges that under the current structure, LIFETECH SCI will contribute investment gains or losses under the equity method, with the short-term earnings per share impact depending on LIFETECH SCI's profitability, timing of completion, and buyback execution. CICC expects that operational improvements and expense optimization will help increase investment income and mitigate dilution, and the company is also expected to continue cash dividends and increase buybacks, maintaining a balance between business expansion and shareholder returns.

Risk Factors

Centralized procurement and medical insurance cost controls exceeding expectations; new product commercialization falling short of expectations; merger and acquisition integration falling short of expectations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment